Eton Pharmaceuticals (NASDAQ:ETON) Given New $17.00 Price Target at HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON) had its price target raised by HC Wainwright from $15.00 to $17.00 in a report issued on Monday, MarketBeat Ratings reports. They currently have a buy rating on the stock.

Separately, Craig Hallum boosted their price objective on Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, October 28th.

Eton Pharmaceuticals Trading Down 6.5 %

ETON stock opened at $12.16 on Monday. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $15.00. The business’s 50-day moving average price is $11.44 and its two-hundred day moving average price is $7.22. The firm has a market cap of $316.78 million, a PE ratio of -55.27 and a beta of 1.38.

Institutional Trading of Eton Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Eton Pharmaceuticals in the 3rd quarter valued at approximately $54,000. Jane Street Group LLC bought a new position in shares of Eton Pharmaceuticals during the 3rd quarter worth approximately $90,000. Renaissance Technologies LLC raised its holdings in shares of Eton Pharmaceuticals by 63.8% in the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after purchasing an additional 41,469 shares during the last quarter. Stonepine Capital Management LLC bought a new stake in shares of Eton Pharmaceuticals in the second quarter worth $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Eton Pharmaceuticals by 86.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after purchasing an additional 30,167 shares during the last quarter. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.